INSM (Insmed) stock outlook for 2026. A qualitative deep dive into the Arikayce revenue base for NTM lung disease, the brensocatib bronchiectasis catalyst, the TPIP pulmonary hypertension pipeline, and the commercialization-transition and cash-burn risks that define this late-stage biotech.
Sarepta Therapeutics (SRPT) Stock Outlook 2026 covering the ELEVIDYS DMD gene therapy, the 2025 patient-death safety events and FDA scrutiny that crushed the stock, the exon-skipping revenue base, RNA and gene-therapy pipeline, binary biotech risk, peer comparison and what global investors should weigh on tax, currency and dilution.
BEAM Beam Therapeutics stock outlook 2026. Base editing technology moat, BEAM-101 sickle cell and beta-thalassemia pipeline, CRSP and NTLA competition, clinical binary risk, cash runway, and a practical positioning framework for investors.
A qualitative deep dive into the 2026 outlook for GC Biopharma (KRX: 006280), Korea's plasma-products leader. We cover the FDA approval and US market push of its immunoglobulin ALYGLO as the core growth catalyst, the vaccine, rare-disease (Hunterase), prescription and consumer-health segments, plasma cost and R&D pressures, earnings volatility and valuation risk, plus practical framing for international investors.
CRSP CRISPR Therapeutics 2026. Casgevy CRISPR therapy, BEAM NTLA BLUE competition, CAR-T pipeline, and commercialization scenarios for investors.